Treatment of Acute Lymphoid Leukemia (ALL) in young adults: treatment intensification according to Pediatric Protocol AIEOP LAL 2000 /Protocol LAL 1308
Project Objectives
The primary Objective is to evaluate the feasibility of the protocol – based on pediatric protocol AIEOP LLA-2000 - in young adults (age between 18 and <35 years). The patients have ALL, a non-mature B cell type, non-Ph+ in terms of the proportion who are under protocol and are alive, in complete remission and eligible to continue the protocol 8 months after diagnosis.
The secondary objectives are:
- To evaluate the CR rate after induction therapy.
- To estimate Overall Survival (OS), Disease Free Survival (DFS) and Event-Free Survival (EFS) rates.
- Retrospective comparison of the results with those obtained in patients with the same clinical features included in GIMEMA protocols.
- To evaluate the toxicity (grade III-IV) associated with a re-induction phase including Adriblastina and Dexamethasone treatments.
- To evaluate the treatment compliance in terms of dose intensity (cumulative doses of drugs and treatment intervals).
Start/End Date
January 26, 2011 - May 2, 2016
Principal Investigator
Prof. Giuseppe Avvisati
Host Institution
Policlinico Umberto I - Rome, Italy
Other Institutions involved
Institutions included in the “Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA)”
Source of funding
Fondazione GIMEMA